SurModics Inc (SRDX)

[DewDiligence]

Re: OctoPlus

>…the main advantage of the product [Locteron] put forward by the company is that patients will need bi-weekly rather than weekly injections during the 48 week treatment period... an incremental advance in my opinion.<

That’s the premise behind HGSI’s Albuferon, and NVS paid big money to license it (#msg-11451787).

Less frequent injections will improve compliance and increase the number of patients who obtain a sustained virologic response. Thus, bi-weekly rather than weekly dosing is a significant advance, IMO.

By using Biolex’s transgenic-plant platform, Locteron may also have lower production costs than Pegasys and Peg-Intron. Regards, Dew